PDK1 and ovarian carcinoma: Thus, metformin treatment can sensitize chemoresistant ovarian cancer cells to cisplatin via the PDK1/HKII pathway, suggesting a potential role of metformin in improving ovarian cancer sensitivity to cisplatin [85].